ARK Genomic Revolution ETF ARKG

Morningstar Medalist Rating

Morningstar’s Analysis ARKG

Will ARKG outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

ARK Genomic Revolution ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings ARKG

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings58.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Tempus AI Inc Class A common stock

9.55182M
Healthcare

Twist Bioscience Corp

8.75167M
Healthcare

10x Genomics Inc Ordinary Shares - Class A

7.69147M
Healthcare

Guardant Health Inc

5.1498M
Healthcare

CRISPR Therapeutics AG

5.0196M
Healthcare

Eli Lilly and Co

4.8693M
Healthcare

Absci Corp

4.8492M
Healthcare

Illumina Inc

4.7991M
Healthcare

Natera Inc

4.4685M
Healthcare

CareDx Inc

3.6770M
Healthcare

Sponsor Center